Fractalkine, also known as CX3CL1, is a unique chemokine that functions as both a soluble protein and a membrane-bound adhesion molecule. Its name derives from its fractal-like structure, featuring a soluble chemokine domain attached to a mucin stalk and a transmembrane domain. Fractalkine is primarily expressed in endothelial cells, neurons, and astrocytes, and it plays a pivotal role in mediating cell adhesion and migration. Its function extends beyond classical chemotaxis; fractalkine is involved in immune cell recruitment, neuronal signaling, and synaptic plasticity. As a transmembrane protein, fractalkine can interact with its receptor CX3CR1 on leukocytes, such as monocytes and T cells, thereby promoting their adhesion to endothelial cells and facilitating their extravasation into tissues. Additionally, the soluble form of fractalkine acts as a chemoattractant for CX3CR1-expressing cells, guiding them to sites of inflammation or tissue injury.
The activation of fractalkine signaling involves a complex interplay between proteolytic cleavage, receptor binding, and downstream signaling events. The proteolytic processing of membrane-bound fractalkine by enzymes such as ADAM10 and ADAM17 results in the release of soluble fractalkine, which can then act on distant cells expressing CX3CR1. Upon binding to its receptor, fractalkine triggers various intracellular signaling pathways, including the MAPK/ERK, PI3K/Akt, and JAK/STAT pathways. These signaling cascades regulate cellular responses such as chemotaxis, cell survival, proliferation, and gene expression. Importantly, fractalkine signaling is tightly regulated to block excessive inflammation and tissue damage. Negative regulators, including decoy receptors and endocytic receptors, help attenuate fractalkine activity by sequestering soluble fractalkine or promoting its internalization and degradation. Moreover, feedback mechanisms exist to modulate fractalkine expression levels and receptor sensitivity in response to environmental cues, ensuring precise control over immune cell recruitment and neuronal function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Direct activator that activates PKC, leading to integrin activation via a CX3CR1-independent pathway. | ||||||
Manganese | 7439-96-5 | sc-250292 | 100 g | $270.00 | ||
Indirect activator that potentiates integrin activation, including ITGAV:ITGB3 and ITGA4:ITGB1, by stabilizing their conformations. | ||||||
Uridine-5′-triphosphate, Trisodium Salt | 19817-92-6 | sc-301964 sc-301964A | 50 mg 1 g | $88.00 $120.00 | 2 | |
Indirect activator that modulates purinergic signaling, promoting integrin activation and cell adhesion. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $451.00 | 3 | |
Indirect activator that inhibits GPCR signaling, including CX3CR1, disrupting chemotaxis and adhesion mediated by Fractalkine. | ||||||
Lipopolysaccharide, E. coli O55:B5 | 93572-42-0 | sc-221855 sc-221855A sc-221855B sc-221855C | 10 mg 25 mg 100 mg 500 mg | $98.00 $171.00 $425.00 $1560.00 | 12 | |
Direct activator that induces Fractalkine expression, amplifying its immune-modulating effects and promoting inflammation. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Indirect activator that modulates intracellular signaling pathways, potentiating Fractalkine-induced cell adhesion and chemotaxis. | ||||||